揭示了Celecoxib纳米结构脂质载体生物可用性的变化,通过HPLC-MS/MS使用氨酸作为增强剂
Yi Zhu1,2, Meiling Chen3, Chuangzan Yang1,2
1Guangdong Pharmaceutical University, Guangzhou, People's Republic of China.
Drug design, development and therapy
|August 5, 2024
概括
氨酸修饰的赛莱可西布纳米结构脂质载体 (HA-NLCs) 显著提高了赛莱可西布的生物可用性,并延长了其作用. 这种配方可降低与口服赛莱科克西布 (celecoxib) 相关的心血管风险.
科学领域:
- 纳米技术在药物输送中的应用
- 药理动力学和提高生物可用性的提高.
- 基于脂质的药物输送系统
背景情况:
- 口服药物管理是为了方便而首选的,但由于药物的溶解性差而受到限制.
- 诸如塞莱科克西布这样的不溶性药物需要高剂量,增加心血管风险.
- 纳米结构脂质载体 (NLCs) 提供了一种提高药物的生物可用性和减少不良影响的策略.
研究的目的:
- 开发氨酸修饰的赛莱科西布纳米结构脂质载体 (HA-NLCs).
- 为了增强赛莱科克西布的生物可用性和减轻药物不良反应.
- 建立可靠的方法来对HA-NLC进行药理动力学分析.
主要方法:
- 使用赛莱科西布和脂质辅助剂制备HA-NLC.
- 为大鼠血样本开发符合FDA标准的生物分析方法.
- 在老鼠中进行的药理动力学研究,以评估HA-NLCs的性能.
主要成果:
- HA-NLCs显示显著增强了塞莱科克西布的吸收,其AUC是Celebrex®的1.54倍.
- 与未经修改的NLCs (CXB-NLCs) 相比,HA-NLCs改善了药物保留时间.
- 在体内,HA-NLC延长了赛莱科克西布的半衰期.
结论:
- HA-NLCs有效地增加了 celecoxib 的口服生物可用性.
- 氨酸修饰延长了赛莱科西布的治疗时间.
- 这种方法可以减少与频繁口服赛莱科克西布剂量相关的心血管风险.
相关概念视频
01:13Bioavailability: Overview
2.7K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.7K
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
190
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
190